Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 1, 2008. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on director share allocation details rather than consolidated financial performance.
Material Changes
On September 30, 2008, Non-Executive Directors were provisionally allocated awards under share allocation arrangements for the service period of July 1, 2008, to September 30, 2008. The allocation prices were set at £12.07 per Ordinary share and $43.49 per American Depository Share (ADS). These allocations were notified to the Company and Directors on October 1, 2008.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Non-Executive Directors received share awards valued at £12.07 per Ordinary share and $43.49 per ADS.
- Allocations were made for the service period ending September 30, 2008.
- Specific share counts were allocated to directors including Sir Christopher Gent (2,796.19 Ordinary Shares) and Mr Lawrence Culp (1,202.22 ADSs).
- This filing does not contain financial performance data for the company.